OBJECTIVE: To summarize evidence for and endorsement of serum urate (SU) as having fulfilled the OMERACT filter as a soluble biomarker in chronic gout at the 2010 Outcome Measures in Rheumatology Meeting (OMERACT 10). METHODS: Data were presented to support the use of SU as a soluble biomarker in chronic gout and specifically the ability to utilize it to predict future patient-reported outcomes. RESULTS: SU was accepted as having fulfilled the OMERACT filter by 78% of voters. However, consensus was not obtained regarding its use as a soluble biomarker in chronic gout. Although the majority of the criteria for a soluble biomarker were fulfilled, the key criterion of association of the biomarker with outcomes was not agreed upon. It was agreed that the appropriate choice of endpoint must be linked to its clinical importance to the individual with the disorder and its temporal relationship to the intervention. Appropriate outcomes in chronic gout may therefore include gout flares, reduction in tophi, and patient-reported outcomes. CONCLUSION: SU is a critical outcome measure. It has the potential to fulfil criteria for a soluble biomarker. Further analyses of existing data from randomized controlled trials will be required to determine whether SU can predict future important outcomes, in particular disability.
OBJECTIVE: To summarize evidence for and endorsement of serum urate (SU) as having fulfilled the OMERACT filter as a soluble biomarker in chronic gout at the 2010 Outcome Measures in Rheumatology Meeting (OMERACT 10). METHODS: Data were presented to support the use of SU as a soluble biomarker in chronic gout and specifically the ability to utilize it to predict future patient-reported outcomes. RESULTS:SU was accepted as having fulfilled the OMERACT filter by 78% of voters. However, consensus was not obtained regarding its use as a soluble biomarker in chronic gout. Although the majority of the criteria for a soluble biomarker were fulfilled, the key criterion of association of the biomarker with outcomes was not agreed upon. It was agreed that the appropriate choice of endpoint must be linked to its clinical importance to the individual with the disorder and its temporal relationship to the intervention. Appropriate outcomes in chronic gout may therefore include gout flares, reduction in tophi, and patient-reported outcomes. CONCLUSION:SU is a critical outcome measure. It has the potential to fulfil criteria for a soluble biomarker. Further analyses of existing data from randomized controlled trials will be required to determine whether SU can predict future important outcomes, in particular disability.
Authors: E L Kanabrocki; J L Third; M D Ryan; B A Nemchausky; P Shirazi; L E Scheving; J B McCormick; R C Hermida; W F Bremner; D A Hoppensteadt; J Fareed; J H Olwin Journal: JAMA Date: 2000-05-03 Impact factor: 56.272
Authors: Nicola Dalbeth; Cathy S Zhong; Rebecca Grainger; Dinesh Khanna; Puja P Khanna; Jasvinder A Singh; Fiona M McQueen; William J Taylor Journal: J Rheumatol Date: 2013-12-15 Impact factor: 4.666
Authors: Jasvinder A Singh; William J Taylor; Nicola Dalbeth; Lee S Simon; John Sundy; Rebecca Grainger; Rieke Alten; Lyn March; Vibeke Strand; George Wells; Dinesh Khanna; Fiona McQueen; Naomi Schlesinger; Annelies Boonen; Maarten Boers; Kenneth G Saag; H Ralph Schumacher; N Lawrence Edwards Journal: J Rheumatol Date: 2013-12-15 Impact factor: 4.666
Authors: Daniel Fb Wright; Matthew P Doogue; Murray L Barclay; Peter T Chapman; Nicholas B Cross; John H Irvine; Lisa K Stamp Journal: Eur J Clin Pharmacol Date: 2016-09-28 Impact factor: 2.953
Authors: Carlo A Scire; Maria Manara; Marco A Cimmino; Marcello Govoni; Fausto Salaffi; Leonardo Punzi; Maria C Monti; Greta Carrara; Carlomaurizio Montecucco; Marco Matucci-Cerinic; Giovanni Minisola Journal: Arthritis Res Ther Date: 2013-08-23 Impact factor: 5.156
Authors: D Vedder; M Gerritsen; B Duvvuri; R F van Vollenhoven; M T Nurmohamed; C Lood Journal: Arthritis Res Ther Date: 2020-06-18 Impact factor: 5.156
Authors: Carlo A Scirè; Greta Carrara; Cinzia Viroli; Marco A Cimmino; William J Taylor; Maria Manara; Marcello Govoni; Fausto Salaffi; Leonardo Punzi; Carlomaurizio Montecucco; Marco Matucci-Cerinic; Giovanni Minisola Journal: Arthritis Care Res (Hoboken) Date: 2016-09-06 Impact factor: 4.794